

Corine Cj Van Marrewijk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6963860/publications.pdf>

Version: 2024-02-01

30
papers

1,912
citations

686830

13
h-index

610482

24
g-index

30
all docs

30
docs citations

30
times ranked

1243
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence and risk factors of late rupture, conversion, and death after endovascular repair of infrarenal aortic aneurysms: The EUROSTAR experience. <i>Journal of Vascular Surgery</i> , 2000, 32, 739-749.	0.6	691
2	Significance of endoleaks after endovascular repair of abdominal aortic aneurysms: The EUROSTAR experience. <i>Journal of Vascular Surgery</i> , 2002, 35, 461-473.	0.6	446
3	Diameter of abdominal aortic aneurysm and outcome of endovascular aneurysm repair: does size matter? A report from EUROSTAR. <i>Journal of Vascular Surgery</i> , 2004, 39, 288-297.	0.6	265
4	The significance and management of different types of endoleaks. <i>Seminars in Vascular Surgery</i> , 2003, 16, 95-102.	1.1	112
5	Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. <i>Leukemia</i> , 2018, 32, 1380-1392.	3.3	66
6	Life expectancy after endovascular versus open abdominal aortic aneurysm repair: Results of a decision analysis model on the basis of data from EUROSTAR. <i>Journal of Vascular Surgery</i> , 2002, 36, 1112-1120.	0.6	65
7	Causes and outcomes of open conversion and aneurysm rupture after endovascular abdominal aortic aneurysm repair: can type ii endoleaks be dangerous?11No competing interests declared.. <i>Journal of the American College of Surgeons</i> , 2002, 194, S98-S102.	0.2	47
8	Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes. <i>Haematologica</i> , 2018, 103, 69-79.	1.7	35
9	Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes. <i>Haematologica</i> , 2020, 105, 632-639.	1.7	35
10	Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry. <i>Haematologica</i> , 2020, 105, 640-651.	1.7	32
11	Genotype-Guided Thiopurine Dosing Does not Lead to Additional Costs in Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 838-845.	0.6	19
12	Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes. <i>Blood Advances</i> , 2018, 2, 2079-2089.	2.5	18
13	Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome. <i>Leukemia</i> , 2021, 35, 1745-1750.	3.3	15
14	Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry. <i>Blood</i> , 2016, 128, 3186-3186.	0.6	14
15	A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS. <i>Blood Advances</i> , 2021, 5, 3066-3075.	2.5	12
16	Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective. <i>Haematologica</i> , 2020, 105, 2516-2523.	1.7	12
17	Development of a core outcome set for myelodysplastic syndromes "a Delphi study from the EUMDS Registry Group. <i>British Journal of Haematology</i> , 2020, 191, 405-417.	1.2	10
18	Core Set of Patient-Reported Outcomes for Myelodysplastic Syndromes - EUMDS Delphi Study in Patients and Hematologists. <i>Blood Advances</i> , 2021, , .	2.5	6

#	ARTICLE	IF	CITATIONS
19	Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS. <i>Leukemia Research</i> , 2018, 67, 21-26.	0.4	4
20	Labile Plasma Iron (LPI) Is a Clinical Indicator of Overt Iron Overload in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry. <i>Blood</i> , 2015, 126, 2865-2865.	0.6	3
21	Mutation Profiles Identify Distinct Clusters of Lower Risk Myelodysplastic Syndromes with Unique Clinical and Biological Features and Clinical Endpoints. <i>Blood</i> , 2020, 136, 29-29.	0.6	2
22	MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination. <i>Blood</i> , 2018, 132, 4357-4357.	0.6	1
23	Excess Mortality in Low-Risk MDS Can be Explained By MDS and AML Related Causes of Death. <i>Blood</i> , 2018, 132, 4385-4385.	0.6	1
24	Validation of the Qualms Questionnaire to Assess Health-Related Quality of Life in European and Israeli Patients with Myelodysplastic Syndromes: Results from the MDS-Right Project. <i>Blood</i> , 2021, 138, 1982-1982.	0.6	1
25	Hepcidin and GDF15 Levels during the First 2 Years Follow-up in Patients with Low and Int-1 Risk Myelodysplastic Syndromes (MDS) from the European Leukemianet MDS Registry. <i>Blood</i> , 2014, 124, 3267-3267.	0.6	0
26	Prognostic Impact of Transfusions Intensity on Survival and Development of Thrombocytopenia in Newly Diagnosed Lower-Risk MDS Patients Participating in the European Leukemianet EU-MDS Registry. <i>Blood</i> , 2015, 126, 1677-1677.	0.6	0
27	Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival. <i>Blood</i> , 2018, 132, 4392-4392.	0.6	0
28	Longitudinal Changes of Impairments in Health-Related Quality of Life in Lower-Risk MDS Patients: A European Leukemianet Study. <i>Blood</i> , 2018, 132, 3097-3097.	0.6	0
29	Deriving Core Patient-Reported Outcomes in Patients with Myelodysplastic Syndromes â€” a Delphi Survey from the European-MDS Registry. <i>Blood</i> , 2018, 132, 2295-2295.	0.6	0
30	Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset. <i>Blood</i> , 2021, 138, 4671-4671.	0.6	0